Vascular Biogenics (NASDAQ: VBLT) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.


How to Become a New Pot Stock Millionaire

This table compares Vascular Biogenics and Applied Genetic Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vascular Biogenics N/A -58.36% -51.16%
Applied Genetic Technologies -33.24% -9.21% -7.35%

Valuation & Earnings

This table compares Vascular Biogenics and Applied Genetic Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vascular Biogenics N/A N/A -$16.00 million ($0.79) -3.29
Applied Genetic Technologies $39.47 million 2.06 $400,000.00 ($0.70) -6.43

Applied Genetic Technologies has higher revenue and earnings than Vascular Biogenics. Applied Genetic Technologies is trading at a lower price-to-earnings ratio than Vascular Biogenics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vascular Biogenics has a beta of -2.44, suggesting that its stock price is 344% less volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.

Institutional and Insider Ownership

5.6% of Vascular Biogenics shares are held by institutional investors. Comparatively, 46.0% of Applied Genetic Technologies shares are held by institutional investors. 5.6% of Applied Genetic Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vascular Biogenics and Applied Genetic Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vascular Biogenics 0 4 0 0 2.00
Applied Genetic Technologies 0 1 5 0 2.83

Vascular Biogenics currently has a consensus price target of $3.33, indicating a potential upside of 28.21%. Applied Genetic Technologies has a consensus price target of $10.17, indicating a potential upside of 125.93%. Given Applied Genetic Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Applied Genetic Technologies is more favorable than Vascular Biogenics.


Applied Genetic Technologies beats Vascular Biogenics on 11 of the 13 factors compared between the two stocks.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.